The most specific indicator of a drug-induced liver injury signal in a clinical trial database is believed to be the occurrence of subjects experiencing drug-associated elevations in both serum ALT and serum total bilirubin ( TB ) without a significant elevation in serum alkaline phosphatase ( ALP ) .
